1. We contribute to the UN’s Global Sustainability Goal for good health and well-being
Healthcare associated infections (HAIs) are a growing problem and constitute a major threat to global public health. HAIs are infections that patients acquire during hospital treatment or when seeking other kinds of healthcare. These infections often occur as a result of medical or surgical procedures. More than half of all HAIs are caused by medical devices.
According to WHO, one in ten patients suffers from an HAI. These infections result in longer hospital stays, greater suffering and more antibiotics being used, which contributes to higher antibiotic resistance.
Antibiotic resistance is one of the most urgent health risks of our time and threatens to undo a century of medical progress,” says Dr. Tedros Adhanom Ghebreyesus, Director General of WHO.
According to WHO, antibiotic resistance threatens the UN’s goal to eradicate the epidemics of, for example, AIDS, tuberculosis and malaria by 2030. Bactiguard’s technology forms an important link in the value chain for healthcare associated infections, as it reduces the risk of infections when using medical devices such as urinary catheters, endotracheal tubes, central venous catheters and implants.
2. Our technology is documented as being effective and safe
Bactiguard’s technology consists of a coating that is applied to medical devices. The coating results in less bacteria adhering to the surface. This reduces the risk of biofilm formation that causes infections.
More than 200 million catheters have been sold so far, and more than 40 clinical studies have been performed, including more than 100,000 patients, who have used products featuring Bactiguard’s technology. It is clinically proven that this technology significantly reduces the risk of infections and that it is safe.
3. Clinical evidence
Clinical studies are becoming increasingly important to verify the efficacy of our products and to increase their use. These studies also increase our knowledge of the problems associated with infections and generate more data about our products.
Clinical studies are important in the sales process. Combined with our knowledge of regulatory requirements and approval processes, they give us a strategic competitive edge when negotiating and developing new license agreeements. This is becoming increasingly clear, as regulations in Europe are moving towards stricter requirements.
Our studies are being performed in Sweden and abroad in collaboration with doctors, nurses, other healthcare professionals and patients. All studies are designed in accordance with international and local laws, rules and ethical principles. They are reviewed and approved by ethical review boards and relevant authorities.
4. Major market potential
We can see major potential on the market for our portfolio of infection prevention products. The Hydrocyn products are very effective and biocompatible. Bactiguard’s technology is safe and adaptable to new applications and areas of use where it is important to reduce the risk of infections.
The technology has been approved both for short-term use and for use on metal implants that will remain in a patient’s body over a long period of time, sometimes for the rest of their life.
We will continue to grow our business by both developing our own product portfolio and entering new license agreements. We will make effective use of the major market potential that we have identified.
5. Clear growth strategy
We are a growth company that has a clear strategy for how we intend to grow. This strategy means that we will develop new products and applications, and expand onto new and existing markets, both with our own products and through new license applications.
In 2020 we started work on building a scalable direct sales organisation for the Nordic region. Through the acquisition of Vigilenz we have gained a well-established sales organisation in Malaysia and a stronger position in South East Asia.
6. Unique market position
Although new antibiotics are being developed, WHO believes that none of them will be effective against the most antibioticresistant bacteria. This is why it is so important to work on preventing infections.
Our coating technology presents a unique opportunity for manufacturers of medical devices and implants to significantly reduce the risk of HAIs, thereby reducing the amount of antibiotics being prescribed.
7. Broad product portfolio for infection prevention
Using our product portfolio of urinary catheters, endotracheal tubes and central venous catheters, we reduce the risk of infections in the areas that are most often subject to HAIs, namely the urinary tract, the respiratory tract and the bloodstream. Approximately two thirds of all HAIs occur in these areas, with medical devices responsible for a high proportion of these infections.
The acquisition of Vigilenz in 2020 has expanded our product portfolio and our market potential by enabling us to enter the market for wound care and disinfection. We can see considerable potential in these areas.
8. License business
One important feature of our business model is our license business. We license our coating technology and our expertise to leading medical device companies. We are in discussions with medtech companies around the world and our goal is to sign 1–2 new license agreements per year.
Our technology has been successfully applied to different types of titanium, stainless steel, latex, silicone, polymers, ceramics and textile materials. It has been approved for both short-term and long-term use, so there are many new applications where it could be used.
9. Profitable growth
Our financial goals are average growth of 20% per year between 2021 and 2025 and an EBITDA margin of at least of 30% at the end of the five-year period (in 2025).
10. Long-term owners and dedicated management
The company’s founders remain the main owners and adopt a long-term approach to their ownership. Swedish institutions also number among our largest owners. The Board of Directors represents wide-ranging experience from industry, entrepreneurship, clinical research and medical experience. Everyone on the Board of Directors owns shares in the company.
The Group management team has extensive experience of the medical device industry as well as sales and marketing. The management team also has experience from major global companies and medical expertise. Everyone in the Group management team owns shares in the company.